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Mutations in chromatin-modifying proteins and transcription factors
are commonly associated with a wide variety of cancers. Through
gain- or loss-of-function, these mutations may result in characteristic
alterations of accessible chromatin, indicative of shifts in the
landscape of regulatory elements genome-wide. The identification
of compounds that reverse a specific chromatin signature could
lead to chemical probes or potential therapies. To explore whether
chromatin accessibility could serve as a platform for small molecule
screening, we adapted formaldehyde-assisted isolation of regula-
tory elements (FAIRE), a chemical method to enrich for nucleosome-
depleted genomic regions, as a high-throughput, automated assay.
After demonstrating the validity and robustness of this approach,
we applied this method to screen an epigenetically targeted small
molecule library by evaluating regions of aberrant nucleosome
depletion mediated by EWSR1-FLI1, the chimeric transcription fac-
tor critical for the bone and soft tissue tumor Ewing sarcoma. As a
class, histone deacetylase inhibitors were greatly overrepresented
among active compounds. These compounds resulted in diminished
accessibility at targeted sites by disrupting transcription of EWSR1-
FLI1. Capitalizing on precise differences in chromatin accessibility for
drug discovery efforts offers significant advantages because it does
not depend on the a priori selection of a single molecular target and
may detect novel biologically relevant pathways.
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Agrowing range of human cancers have been associated withmutations in genes encoding proteins that regulate chro-
matin, the assembly of proteins and DNA that control DNA-
templated processes, including transcription and replication (1, 2).
Small molecule drugs and chemical probes offer an approach to
explore the biological consequences of these mutations and are
emerging as a therapeutic strategy to target disease pathways.
Drugs targeting histone deacetylase (HDAC) enzymes, the bro-
modomain reader BRD4, and DNA methylation have already
received regulatory approval or have entered clinical testing, and
chemical probes have been developed against a broad range of
chromatin regulators, such as the methyltransferases (3) DOT1L
(4), EZH2 (5–8), and G9a (9, 10), and the reader proteins
L3MBTL3 (11) and BRD4 (12–14). However, transcription fac-
tors that lack enzymatic activity or binding pockets with targetable
molecular features have been considered “undruggable,” and a
reductionist approach based on identification of their molec-
ular targets has largely failed.
The majority of Ewing sarcomas, highly malignant pediatric
bone and soft tissue tumors, harbor a chromosomal translocation
that joins the amino-terminal domain of EWSR1 with the DNA
binding domain of the ETS transcription factor family member
FLI1 to generate the chimeric transcription factor EWSR1-FLI1
(15). Translocations with other ETS genes are detected in most
of the remaining tumors, yielding similarly functioning fusion
proteins (16). We recently found that, despite conservation of
the ETS DNA binding domain, the fusion oncoprotein uniquely
localizes to specific microsatellite regions (17, 18). Using form-
aldehyde-assisted isolation of regulatory elements (FAIRE), a
biochemical strategy to enrich for nucleosome-depleted regions
of chromatin, we demonstrated that EWSR1-FLI1 binding was
necessary to maintain nucleosome depletion at these sites. The
mechanism through which EWSR1-FLI1 modifies chromatin re-
mains unknown. Because EWSR1-FLI1 does not possess recog-
nizable catalytic activity, other yet-to-be-identified proteins likely
mediate its ability to remodel chromatin.
The absence of a biochemical mechanism would typically pose
challenges for chemical targeting. However, we hypothesized
that reversing a unique chromatin signature could serve as a
strategy to discover small molecules with activity toward EWSR1-
FLI1. To target this activity, we adapted and validated FAIRE as
an automated, high-throughput tool and applied this method to
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evaluate a focused set of small molecules designed to interact
with proteins that regulate chromatin. Because this approach di-
rectly assessed the effects of compounds on a specific, disease-
associated aberrant chromatin signature, while remaining agnostic
about precise molecular mechanisms, it enabled the discovery of
agents that affect the underlying molecular defect without re-
quiring an a priori selection of molecular targets.
Results
Validation of Column-Based FAIRE. As currently applied, FAIRE, a
biochemical assay for the enrichment of nucleosome-depleted
regions of the genome, is dependent on organic extraction with a
mixture of phenol and chloroform. Because this critical extraction
step is not easily automated, we adapted and miniaturized FAIRE
by substituting organic extraction with solid-phase selection and
robotic automation, hereafter termed high-throughput FAIRE
(HT-FAIRE) (Fig. 1A). Because the chromatin fractionation step
is central to this technique, we compared the performance of these
methods. Quantitative locus-specific testing demonstrated that
both approaches offered concordant enrichment at a series of
promoter and enhancer regions (Fig. S1). We then compared the
performance of both methods genome-wide. We used primary
human umbilical vein endothelial cells (HUVECs) since multiple
genomic datasets exploring chromatin features have been gener-
ated for these cells permitting subsequent integrative analyses of
the FAIRE results [Encyclopedia of DNA Elements (ENCODE)
Tier 2] (19). HT-FAIRE demonstrated signal enrichment patterns
similar to those observed using standard FAIRE. For example,
enrichment at transcriptional start sites (TSSs), including posi-
tive correlation with RNA abundance as well as enrichment at
CCCTC-binding factor (CTCF) sites demonstrated similar char-
acteristics as previously reported FAIRE studies (Fig. 1 B–D) (20).
Signal enrichment by HT-FAIRE was less robust at TSSs, con-
sistent with the quantitative PCR (qPCR) results. Of the top
10,000 nucleosome-depleted regions detected in HUVECs by
HT-FAIRE, ∼90% overlapped those sites identified by standard
FAIRE. In contrast, fewer than 50% of enriched regions over-
lapped FAIRE sites from any of six other cell lines (Fig. S2A),
demonstrating that HT-FAIRE offers a level of specificity similar
to that reported in previous studies (21).
Fig. 1. Comparison of FAIRE methodologies. (A) Flow diagram comparing column-based and standard FAIRE methods. (B) Heatmap representation of
normalized FAIRE enrichment (±3 kb from TSS) using standard (Left) or column (Right) FAIRE in HUVEC. (C) Normalized FAIRE signal from both methods ±3 kb
from TSS. (D) Normalized FAIRE signal from both methods ±3 kb around HUVEC CTCF sites (ENCODE). (E) Hierarchical clustering analysis of 500-bp intervals
demonstrating differential FAIRE signals across seven cell types, as well as HUVEC HT-FAIRE. Platform-specific (clusters 1 and 3) and cell type-specific (cluster 2)
clusters were identified. (F) Fractional overlap annotation of clusters 1–3, with histone modifications and transcription factors (ENCODE).











We then examined those genomic regions that most discrim-
inate HT-FAIRE and standard FAIRE and also demonstrate
HUVEC cell-type specificity. Hierarchical clustering of these
∼9,700 genomic regions identified three groups (Fig. 1E). Cluster
1 (1,805 regions) consisted of those regions enriched in all cell
lines when assayed by standard FAIRE but not by HT-FAIRE.
Cluster 2 (6,017 regions), by far the largest, consisted of regions
with HUVEC-specific signal enrichment that was detected by both
HT-FAIRE and standard FAIRE. Cluster 3 (843 regions) con-
sisted of regions selectively identified by HT-FAIRE. Regions in
each cluster were then associated with genes [Genome Regions
Enrichment of Annotations Tool (GREAT)] (22). As expected,
the HUVEC-selective sites detected by both HT-FAIRE and
standard FAIRE (cluster 2) were tightly linked with endothelial
cell ontologies, including angiogenesis (q = 4.4 × 10−12) and reg-
ulation of cell-substrate adhesion (q = 6.5 × 10−7) (Fig. S2B). No
significant gene ontologies were associated with the regions in
the other clusters. To test whether FAIRE-enriched regions
were likely to harbor regulatory elements, we annotated the sites
from each cluster with active and repressive histone modifications.
We also tested for association with targeting of numerous tran-
scription factors, including those known to be important in en-
dothelial cell biology, as assessed by ChIP-seq (17, 19). (Fig. 1F).
Sites in cluster 2 (common to both platforms, HUVEC-specific)
were associated primarily with active histone modifications, as well
as sites targeted by FLI1, FOS, JUN, GATA2, and RNA Poly-
merase II. The prevalence of putative FLI1 and FOS/JUN binding
sites was corroborated by the enrichment of ETS and AP1 DNA
sequence motifs in these regions (P < 1 × 10−800) (Fig. S2C). ETS
(specifically ETV2) and AP1 factors are both known to play
prominent roles in endothelial development (23, 24). Regions in
cluster 1 were more closely associated with repressive modifica-
tions and EZH2 binding (Fig. 1F). Clusters 1 and 3 were distin-
guished by enrichment for repetitive regions, with each cluster
associated with a specific repetitive element class: satellites (82%
of cluster 1 sites) and simple repeats (71% of cluster 3 sites) (Fig.
S2D). We also noted a difference in sequence composition be-
tween cluster 1 and clusters 2 and 3 (Fig. S2E). The basis of their
differential enrichment may reflect chromatin variation at these
regions that are distinguished by the biochemical properties spe-
cific to organic or solid phase purification. Because we used
published standard FAIRE datasets that were generated with a
shorter sequencing read length (ENCODE, 36-bp reads), we
asked whether the difference in read length could partially ac-
count for the variability in mapping and sequence content at
clusters 1 and 3 (Fig. S2F). Repeating these analyses after trun-
cating the HT-FAIRE sequencing reads to 36 bp did not change
the hierarchical clustering or histone modification associations
(Fig. S2 G and H). Taken together, these data demonstrate that
HT-FAIRE performs similarly to standard FAIRE and identifies
regions that are biologically meaningful.
Application of HT-FAIRE to Small Molecule Screening.We then adapted
HT-FAIRE for high-throughput automation and applied it in a
targeted screen. The screen was based on two regions selected from
a set of Ewing sarcoma-specific sites that we had previously shown
were accessible in multiple Ewing sarcoma cell lines with accessi-
bility that was dependent on continued expression of EWSR1-FLI1
(17). Regions that consistently demonstrate FAIRE enrichment or
lack of enrichment across many cell types were included as controls
(see Table S3).
We performed the screen using a custom library that consisted
of 640 small molecules, including those designed to target his-
tone methyltransferases, methyl lysine reader proteins, histone
demethylases and deacetylases, DNA methyltransferases, and
acetyl-lysine reader proteins. The compound collection included
well-annotated molecular profiles (chemical probes) (25), as well
as compounds that were designed around several chemical scaffolds
originally directed toward specific targets of interest (methyl-lysine
readers and transferases). The latter compounds have only
been tested in vitro for activity on the proteins for which they
were designed and likely have effects on other molecular tar-
gets. We hypothesized that the inclusion of a large number of
uncharacterized compounds would increase the potential to
identify previously unanticipated protein targets.
After optimizing conditions for growth and DMSO tolerance
(Fig. S3), Ewing sarcoma patient-derived cells (EWS894) were
exposed to 10 μM of each compound (or DMSO control) for 16 h
in a 96-well format. The unit automation pipeline separated each of
two 384-well compound plates containing the library into four 96-
well plates for screening (Fig. S4). After application of HT-FAIRE,
chromatin from the 96-well plates was combined into a 384-well
plate format for qPCR-based testing of the signature and control
regions in two technical replicates. The positive control region
demonstrated a significant difference in FAIRE signal over the
background control (plate 1, P = 7.50e−53; plate 2, P = 6.63e−98).
Critically, signals from each of the disease-specific regions were
highly concordant (Pearson r = 0.8764), which supported combining
the values from both sites for subsequent analytics (Fig. 2A).
To quantify the degree to which chromatin accessibility changed
after compound treatment, we calculated a “relative chromatin
inhibition” (RCI) score that compared the relative enrichment at
the oncogene-targeted regions with that at the positive control re-
gion. An RCI score of 1.0 was considered “no change.” Com-
pounds that similarly affected both the oncogene-targeted and
control regions were considered nonspecific. DMSO (vehicle) and
UNC0638 (10) (a chemical probe that we had previously de-
termined not to affect aberrantly open chromatin in Ewing sarcoma
cells) demonstrated an RCI of 1.0 (Fig. 2B and Fig. S5A). Because
this primary screen was based on a single measurement, we per-
mitted greater intersample variability, defining compounds with an
RCI value greater than two SDs from the mean RCI score for
Fig. 2. Chromatin signature-based screen identified a cluster of HDAC in-
hibitors that significantly decreased EWSR1-FLI1–dependent chromatin ac-
cessibility. (A) The LOG10-transformed relative chromatin inhibition (RCI)
scores for the Ewing sarcoma-specific P1 and P7 regions are plotted (Pearson
r = 0.8764). (B) RCI scores for DMSO and a negative control compound,
UNC0638, are plotted for each 384-well plate. An RCI score of 1.0 indicates
no change (dotted line). Error bars are the SD of 16 replicates. (C and D) Plate
1 (C) or plate 2 (D) LOG2 ratio of the RCI values was plotted against the rank
order of compounds from greatest relative decrease (Top, left side of x axis)
to the greatest relative increase (Top, right side of x axis) in FAIRE signal. The
dashed lines indicate the significance cutoff of RCI values ≥2 SDs or ≤2 SDs
from the average RCI for DMSO controls. Thirty compounds that show the
greatest decrease in FAIRE signal for each plate are magnified (Bottom
graph). The bars representing HDAC inhibitors are highlighted in magenta.
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DMSO-treated controls as “hits” (Fig. 2B and Fig. S5A) (26). Fifty-
eight compounds met criteria for reduced chromatin accessibility
(Fig. 2 C and D). Forty-three of these compounds were unchar-
acterized, 14 of which were analogs within a single chemical scaf-
fold, and 15 were characterized chemical probes. Treatment with
20 compounds resulted in increased FAIRE signals, all of which
were uncharacterized (Table S1). Because the goal of this study was
to inhibit EWSR1-FLI1–mediated aberrant chromatin accessibility,
we focused on those compounds that decreased the FAIRE signal.
We prepared a secondary screen plate that contained all hit
compounds and 16 compounds that failed to show a change in
chromatin accessibility in the initial screen (RCI of 1.0, no
change). This secondary screen was performed on three in-
dependent replicates of EWS894 cells, permitting a more strin-
gent threshold of 3 SDs from the mean RCI score to define hits
(26, 27). Fifteen compounds (26%) met this enhanced threshold
(Fig. 3A and Fig. S5B).
Remarkably, of the 21 HDAC inhibitors that were included in
our library, 14 of these compounds scored as hits in both the
primary and secondary screens (Fig. 3A). We compared the
specificity of the active and inactive HDAC inhibitors (Table
S2). Although the majority of the inhibitors in our set have
known activity against multiple HDAC proteins, making it dif-
ficult to identify the specific HDAC target, inhibitors selective
for HDAC6 (Tubastatin) (28) and HDAC8 (PCI-34051) (29) did
not score in our screen, making it unlikely that either of these
HDAC proteins is involved in maintaining aberrant chromatin
accessibility in Ewing sarcoma. The overall reproducibility of the
screen confirms the robustness of HT-FAIRE as an approach
for discovering biologically relevant compounds using a small,
focused compound library. A priori selection of inhibitors of
HDAC proteins as lead candidates for screening would have been
unlikely because histone hyperacetylation is commonly associated
with destabilized nucleosomes and open chromatin.
To replicate the results of the screen, we focused on two hit
compounds, Vorinostat and Panobinostat because these hydrox-
amate derivatives inhibit multiple classes of HDACs and have
received FDA approval for oncological indications (30). Treat-
ment of EWS894 cells with either of these compounds followed
by HT-FAIRE resulted in a dose-dependent decrease in chro-
matin accessibility (Fig. S6A). This decrease was not observed
with an HDAC inhibitor that did not score as a hit in our screen
(Tubastatin), or a compound with an unrelated structure and
protein target.
We then validated the compounds that emerged from our
screen using standard FAIRE. FAIRE signals from cells treated
with Panobinostat decreased at the test regions to a similar extent
(approximately twofold) to that observed in the screen and also
demonstrated a similar effect on two additional EWSR1-FLI1–tar-
geted sites (Fig. 3B). Critically, positive control regions remained
unaffected, demonstrating that the decreased RCI was not the result
of increased signals at the control regions. We then validated the
effect of additional HDAC inhibitors by standard FAIRE. Pan-
obinostat, Vorinostat, and AR-42 demonstrated a similar magnitude
effect on chromatin (Fig. 3C). Panobinostat also led to a dose-
dependent decrease in FAIRE signal at an EWSR1-FLI1–targeted
site (Fig. 3D). As further validation, we performed FAIRE-qPCR
in two additional patient-derived EWSR1-FLI1–expressing Ewing
sarcoma cell lines, EWS502 (Fig. S6B) and RD-ES (Fig. S6C).
Panobinostat treatment significantly decreased FAIRE signals at
EWSR1-FLI1 binding sites in both of these cell lines. Together, these
data confirm that HDAC inhibitors are associated with reduced
chromatin accessibility at EWSR1-FLI1–targeted regions as mea-
sured by both HT-FAIRE and standard FAIRE.
To explore the mechanism underlying the chromatin signature
reversal, we asked whether EWSR1-FLI1 levels were affected by
HDAC inhibitor treatment. Panobinostat and Vorinostat treatment
resulted in a dose-dependent decrease in EWSR1-FLI1 mRNA
levels whereas Tubastatin had no effect (Fig. 4A). Consistent with
the decrease in mRNA, EWSR1-FLI1 protein levels were also
decreased after treatment with Panobinostat and Vorinostat
(Fig. 4B). Tubastatin did not affect EWSR1-FLI1 protein levels
although a slight overall decrease was noted at 10 μM (Fig. 4B).
These data suggest that Panobinostat and Vorinostat, both hit
compounds identified in the HT-FAIRE screen, decrease levels
of EWSR1-FLI1 by altering transcription.
We then asked whether ectopically expressed EWSR1-FLI1
would be similarly affected by HDAC inhibition. We generated a
Ewing sarcoma cell line in which the endogenous EWSR1-FLI1
was silenced with concurrent stable expression of lentivirally
transduced EWSR1-FLI1. Panobinostat or Vorinostat treatment
of these cells did not affect EWSR1-FLI1mRNA levels (Fig. 4C).
Correspondingly, treatment with multiple HDAC inhibitors had
virtually no effect on exogenous EWSR1-FLI1 protein levels (Fig.
4D), in contrast to the endogenous protein (Fig. S7A). These data
demonstrate that HDAC inhibition acts through transcription of
the EWSR1-FLI1 without affecting protein stability.
Fig. 3. HDAC inhibitors affect EWSR1-FLI1 chromatin accessibility in a dose-
dependent manner. (A) Secondary screen that included all hit compounds
from plate 1 and plate 2 and a selection of compounds that did not score.
LOG2 ratio of the RCI values as described for Fig. 2 C and D. The dashed lines
indicate the significance cutoff of RCI values ≥3 SDs or ≤3 SDs from the
average RCI for vehicle-treated controls. The bars representing HDAC inhibi-
tors are highlighted in magenta. (B) Standard FAIRE-qPCR was performed on
EWS894 cells treated with Panobinostat for EWSR1-FLI1 target sites (1, P1; 2,
P7; 3, target 3; 4, target 4) (Table S3) and control sites (1, AURKAIP1; 2, control 2)
(Table S3). (C) Standard FAIRE-qPCR (target sites P1, P7; control site AURKAIP1)
was performed on EWS894 cells treated with Vorinostat, AR-42, or Panobino-
stat. (D) FAIRE-qPCR was performed on an EWSR1-FLI1 binding site (P1) and a
control site (AURKAIP1) after treatment of EWS894 cells with DMSO or 10-fold
dilutions of Panobinostat (10 μM to 0.01 μM). All treatments were 10 μM for
16 h unless otherwise noted. FAIRE is plotted relative to DMSO control, and error
bars represent the SD of three replicates.











We then tested chromatin accessibility in the EWSR1-FLI1–
transduced Ewing sarcoma cells. Treatment with multiple HDAC
inhibitors failed to affect FAIRE signals at oncogene-targeted
regions (Fig. 4E). These results were replicated in a second Ewing
sarcoma cell line (EWS502) that similarly ectopically expresses
EWSR1-FLI1 (Fig. S7B). Taken together, these data suggest that
the loss of chromatin accessibility at EWSR1-FLI1 binding sites
results from HDAC inhibition-mediated alteration in EWSR1-FLI1
transcription, thereby suppressing oncoprotein levels, rather than
HDAC activity directly on chromatin at target sites.
Discussion
In contrast to previous efforts to inhibit EWSR1-FLI1 activity
that have capitalized on individual target gene expression or
physical interactions (31–36), the application of HT-FAIRE
offered a strategy to identify therapeutics based on variation
in chromatin accessibility, a universal genomic feature deter-
mined by the combined effects of transcriptional regulators
and chromatin regulatory proteins (37). Indeed, FAIRE has
been shown to detect specific chromatin changes resulting
from treatment with anthracyclines that directly interact with
DNA (38, 39), thereby demonstrating the utility of this assay
to explore the function of small molecule compounds. Unlike
chromatin immunoprecipitation (ChIP), FAIRE does not de-
pend on the prior selection of a specific target. Without the
need for an enzymatic processing step, FAIRE does not require
the optimization (and consequent variability) associated with
DNase, MNase, or Assay for Transposase-Accessible Chromatin
(ATAC) (40), other techniques that explore chromatin acces-
sibility. A specific chromatin signature associated with multiple
molecular mechanisms can form the basis for an HT-FAIRE
functional screen.
The identification of HDAC inhibitors was unanticipated be-
cause the screen sought to identify compounds associated with a
selective decrease in chromatin accessibility, a feature associated
with histone hypoacetylation. The unexpected outcome high-
lights an advantage of functionally screening a broad compound
library to identify molecules that act directly and indirectly. We
found that HDAC inhibitors decreased EWSR1-FLI1 levels,
which explained the decreased accessibility of chromatin at tar-
geted microsatellite repeat regions. The connection between
HDAC activity and Ewing sarcoma has been noted previously.
Romedepsin had been shown to decrease EWSR1-FLI1 mRNA
levels (41), and Romedepsin, Vorinostat, and Entinostat exhibited
anti-proliferative activity on Ewing cells (41, 42). In addition,
Vorinostat treatment reversed the EWSR1-FLI1–mediated tran-
scriptional repressive signature in Ewing sarcoma cells (43). Each
of the HDAC inhibitors previously associated with effects on
Ewing sarcoma were identified in our screen.
The exact role of HDAC inhibitors on EWSR1-FLI1 tran-
scription is not understood. HDAC activity in transcription is
complex because HDAC proteins can have both histone and
nonhistone protein targets, can function as the catalytic subunits
of multiple corepressor complexes including Sin3A, NuRD,
NCoR/SMRT, and CoREST (44, 45), and are known to function
in transcriptional elongation, which may selectively affect highly
expressed genes in cancers (46, 47). Because HDAC inhibitors
often target multiple HDAC proteins, each with variable po-
tency, they can result in a pleiotropic effect on cellular pathways,
making specific effects challenging to interpret. The selective
HDAC inhibitors in our library targeted HDAC6 (Tubastatin)
(28) or HDAC8 (PCI-34051) (29) and did not alter the Ewing
chromatin signature in our screen (Table S2). For the pan-
HDAC inhibitors that failed to decrease Ewing FAIRE signals, it
is possible that the concentrations used were insufficient to in-
hibit the relevant HDAC protein(s).
In conclusion, we developed an approach to screen com-
pounds based on changes in chromatin. HT-FAIRE is applicable
to any cellular model associated with a specific chromatin ac-
cessibility signature and offers a general strategy to disrupt the
function of proteins lacking structure amenable to small mole-
cule targeting or the absence of complete characterization of the
biochemical pathways and partners. The chemical probes iden-
tified by this method can offer mechanistic insights into chro-
matin dysregulation in disease, can lead to the identification of
valid molecular targets, and can serve as starting points for drug
discovery efforts.
Methods
Cell Culture and Western Analysis. EWS894 and EWS502 cells (48) were cul-
tured in RPMI-1640 supplemented with 15% (vol/vol) FBS and maintained at
standard growth conditions of 37 °C and 5% CO2. Proteins were extracted
using 2× Laemmli buffer, were separated by SDS/PAGE, and were then
transferred onto nitrocellulose and probed for EWSR1-FLI1 (ab15289;
Abcam) or tubulin (T9026; Sigma) and fluorescent secondary antibodies and
quantified (LiCor).
Fig. 4. EWSR1-FLI1 mRNA and protein levels are decreased after HDAC in-
hibition. (A) EWSR1-FLI1 mRNA levels were measured by qRT-PCR after
treatment of EWS894 cells with indicated concentrations of Panobinostat,
Vorinostat, or Tubastatin. (B) EWS894 cells were treated with varying con-
centrations of Panobinostat, Vorinostat, or Tubastatin (threefold dilutions,
10 μM to 0.001 μM). Cell extracts were assayed for EWSR1-FLI1 (“E-F”) and
tubulin protein levels by immunoblot. All treatments were for 16 h. (C) EWS894
cells lentivirally transduced with EWSR1-FLI1 were treated with varying concen-
trations of Panobinostat or Vorinostat. RNA was measured by qRT-PCR.
(D) Transduced EWSR1-FLI1 protein levels were measured in EWS894 cells after
treatment with HDAC inhibitors (10 μM) by immunoblotting. (E) FAIRE-qPCR
measuring chromatin accessibility in EWS894 cells with exogenous EWSR1-FLI1
after treatment with 10 μM multiple HDAC inhibitors. All treatments were
for 16 h. Error bars represent the SD of three technical replicates (C and E) or
three biological replicates (D).
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Standard FAIRE, HT-FAIRE, and RNA Extraction. FAIRE for sequencing was as
follows: Replicate samples of chromatin from 2 × 107 cells were divided.
Equal portions were used for standard FAIRE, as described (20), or HT-FAIRE,
using a ChIP DNA clean and concentrate column (11-379; Zymo Research) as
per the manufacturer’s instructions. FAIRE DNA from both replicates was
prepared as per the manufacturer’s recommendations (TruSeq DNA Sample
Prep Kit; Illumina), and 50-bp reads were sequenced (HiSeq 2000; Illumina)
at the University of North Carolina High-Throughput Sequencing Facility. A
detailed version of the automated, high-throughput FAIRE screen is outlined
in SI Methods. Cells in a 96-well format were incubated for 16 h with compound
or vehicle at a final concentration of 10 μM. After formaldehyde cross-linking, cells
were sonicated in Lysis Buffer A (20). Input was collected from untreated cells in
the first column of each plate, and FAIRE was performed on remaining samples
using columns (D5207; Zymo Research). Relative chromatin inhibition was de-
termined by performing qPCR on FAIRE and input samples. Primer sequences are
listed in Table S3. RNA was extracted (74134; Qiagen) followed by cDNA synthesis
(Superscript III; Invitrogen). Ten microliters of qPCR reactions (SYBR Green
Mastermix; Bio-Rad or Biotool) were performed according to the manufac-
turers’ instructions. qPCR for FAIRE and cDNA was performed (ViiA7 Real-Time
PCR system; Applied Biosystems) and analyzed using the ΔΔCt method (49).
Analysis of Standard FAIRE and HT-FAIRE. Sequencing data were analyzed as
described in ref. 37. A detailed description of the analyses is available in
SI Methods.
ACKNOWLEDGMENTS. We thank J. Lieb, D. Kireev, L. James, and members
of the I.J.D. laboratory for meaningful discussions, and J. Jin for the UNC0638
compound. These studies were supported by the Wide Open Charitable
Foundation, the V Foundation for Cancer Research, National Institutes
of Health (NIH) Grants R01CA166447 (to I.J.D.) and RC1GM090732 and
R01GM100919 (to S.V.F.), the Carolina Partnership, and the University Cancer
Research Fund, University of North Carolina at Chapel Hill. A.W. was supported
in part by NIH Grants T32CA071341 and T32GM007092 and J.T. was supported
in part by Reelin’ for Research.
1. Plass C, et al. (2013) Mutations in regulators of the epigenome and their connections
to global chromatin patterns in cancer. Nat Rev Genet 14(11):765–780.
2. Waldmann T, Schneider R (2013) Targeting histone modifications: Epigenetics in
cancer. Curr Opin Cell Biol 25(2):184–189.
3. Kaniskan HÜ, Konze KD, Jin J (2015) Selective inhibitors of protein methyl-
transferases. J Med Chem 58(4):1596–1629.
4. Daigle SR, et al. (2013) Potent inhibition of DOT1L as treatment of MLL-fusion leu-
kemia. Blood 122(6):1017–1025.
5. Knutson SK, et al. (2012) A selective inhibitor of EZH2 blocks H3K27 methylation and
kills mutant lymphoma cells. Nat Chem Biol 8(11):890–896.
6. Konze KD, et al. (2013) An orally bioavailable chemical probe of the lysine methyl-
transferases EZH2 and EZH1. ACS Chem Biol 8(6):1324–1334.
7. McCabe MT, et al. (2012) EZH2 inhibition as a therapeutic strategy for lymphoma with
EZH2-activating mutations. Nature 492(7427):108–112.
8. Qi W, et al. (2012) Selective inhibition of Ezh2 by a small molecule inhibitor blocks
tumor cells proliferation. Proc Natl Acad Sci USA 109(52):21360–21365.
9. Liu F, et al. (2013) Discovery of an in vivo chemical probe of the lysine methyl-
transferases G9a and GLP. J Med Chem 56(21):8931–8942.
10. Vedadi M, et al. (2011) A chemical probe selectively inhibits G9a and GLP methyl-
transferase activity in cells. Nat Chem Biol 7(8):566–574.
11. James LI, et al. (2013) Discovery of a chemical probe for the L3MBTL3 methyllysine
reader domain. Nat Chem Biol 9(3):184–191.
12. Filippakopoulos P, et al. (2010) Selective inhibition of BET bromodomains. Nature
468(7327):1067–1073.
13. Dawson MA, et al. (2011) Inhibition of BET recruitment to chromatin as an effective
treatment for MLL-fusion leukaemia. Nature 478(7370):529–533.
14. Nicodeme E, et al. (2010) Suppression of inflammation by a synthetic histone mimic.
Nature 468(7327):1119–1123.
15. Delattre O, et al. (1992) Gene fusion with an ETS DNA-binding domain caused by
chromosome translocation in human tumours. Nature 359(6391):162–165.
16. Delattre O, et al. (1994) The Ewing family of tumors: A subgroup of small-round-cell
tumors defined by specific chimeric transcripts. N Engl J Med 331(5):294–299.
17. Patel M, et al. (2012) Tumor-specific retargeting of an oncogenic transcription factor
chimera results in dysregulation of chromatin and transcription. Genome Res 22(2):
259–270.
18. Gangwal K, et al. (2008) Microsatellites as EWS/FLI response elements in Ewing’s
sarcoma. Proc Natl Acad Sci USA 105(29):10149–10154.
19. Consortium EP, et al.; ENCODE Project Consortium (2012) An integrated encyclopedia
of DNA elements in the human genome. Nature 489(7414):57–74.
20. Simon JM, Giresi PG, Davis IJ, Lieb JD (2012) Using formaldehyde-assisted isolation of
regulatory elements (FAIRE) to isolate active regulatory DNA. Nat Protoc 7(2):
256–267.
21. Song L, et al. (2011) Open chromatin defined by DNaseI and FAIRE identifies regu-
latory elements that shape cell-type identity. Genome Res 21(10):1757–1767.
22. McLean CY, et al. (2010) GREAT improves functional interpretation of cis-regulatory
regions. Nat Biotechnol 28(5):495–501.
23. De Val S, Black BL (2009) Transcriptional control of endothelial cell development. Dev
Cell 16(2):180–195.
24. Meadows SM, Myers CT, Krieg PA (2011) Regulation of endothelial cell development
by ETS transcription factors. Semin Cell Dev Biol 22(9):976–984.
25. Frye SV (2010) The art of the chemical probe. Nat Chem Biol 6(3):159–161.
26. Malo N, Hanley JA, Cerquozzi S, Pelletier J, Nadon R (2006) Statistical practice in high-
throughput screening data analysis. Nat Biotechnol 24(2):167–175.
27. Caraus I, Alsuwailem AA, Nadon R, Makarenkov V (2015) Detecting and overcoming
systematic bias in high-throughput screening technologies: A comprehensive review
of practical issues and methodological solutions. Brief Bioinform 16(6):974–986.
28. Butler KV, et al. (2010) Rational design and simple chemistry yield a superior, neu-
roprotective HDAC6 inhibitor, tubastatin A. J Am Chem Soc 132(31):10842–10846.
29. Balasubramanian S, et al. (2008) A novel histone deacetylase 8 (HDAC8)-specific in-
hibitor PCI-34051 induces apoptosis in T-cell lymphomas. Leukemia 22(5):1026–1034.
30. Falkenberg KJ, Johnstone RW (2014) Histone deacetylases and their inhibitors in
cancer, neurological diseases and immune disorders. Nat Rev Drug Discov 13(9):
673–691.
31. Stegmaier K, et al. (2007) Signature-based small molecule screening identifies cyto-
sine arabinoside as an EWS/FLI modulator in Ewing sarcoma. PLoS Med 4(4):e122.
32. Erkizan HV, et al. (2009) A small molecule blocking oncogenic protein EWS-FLI1 in-
teraction with RNA helicase A inhibits growth of Ewing’s sarcoma. Nat Med 15(7):
750–756.
33. Sankar S, et al. (2014) Reversible LSD1 inhibition interferes with global EWS/ETS
transcriptional activity and impedes Ewing sarcoma tumor growth. Clin Cancer Res
20(17):4584–4597.
34. Owen LA, Kowalewski AA, Lessnick SL (2008) EWS/FLI mediates transcriptional re-
pression via NKX2.2 during oncogenic transformation in Ewing’s sarcoma. PLoS One
3(4):e1965.
35. Boro A, et al. (2012) Small-molecule screen identifies modulators of EWS/FLI1 target
gene expression and cell survival in Ewing’s sarcoma. Int J Cancer 131(9):2153–2164.
36. Kovar H (2014) Blocking the road, stopping the engine or killing the driver? Advances
in targeting EWS/FLI-1 fusion in Ewing sarcoma as novel therapy. Expert Opin Ther
Targets 18(11):1315–1328.
37. Simon JM, et al. (2014) Variation in chromatin accessibility in human kidney cancer
links H3K36 methyltransferase loss with widespread RNA processing defects. Genome
Res 24(2):241–250.
38. Pang B, de Jong J, Qiao X, Wessels LF, Neefjes J (2015) Chemical profiling of the
genome with anti-cancer drugs defines target specificities. Nat Chem Biol 11(7):
472–480.
39. Pang B, et al. (2013) Drug-induced histone eviction from open chromatin contributes
to the chemotherapeutic effects of doxorubicin. Nat Commun 4:1908.
40. Tsompana M, Buck MJ (2014) Chromatin accessibility: A window into the genome.
Epigenetics Chromatin 7(1):33.
41. Sakimura R, et al. (2005) Antitumor effects of histone deacetylase inhibitor on
Ewing’s family tumors. Int J Cancer 116(5):784–792.
42. Sonnemann J, et al. (2007) Histone deacetylase inhibitors induce cell death and en-
hance the apoptosis-inducing activity of TRAIL in Ewing’s sarcoma cells. J Cancer Res
Clin Oncol 133(11):847–858.
43. Sankar S, et al. (2013) Mechanism and relevance of EWS/FLI-mediated transcriptional
repression in Ewing sarcoma. Oncogene 32(42):5089–5100.
44. Singh BN, et al. (2010) Nonhistone protein acetylation as cancer therapy targets.
Expert Rev Anticancer Ther 10(6):935–954.
45. Delcuve GP, Khan DH, Davie JR (2013) Targeting class I histone deacetylases in cancer
therapy. Expert Opin Ther Targets 17(1):29–41.
46. Kim YJ, et al. (2013) HDAC inhibitors induce transcriptional repression of high copy
number genes in breast cancer through elongation blockade. Oncogene 32(23):
2828–2835.
47. Yokoyama S, et al. (2008) Pharmacologic suppression of MITF expression via HDAC
inhibitors in the melanocyte lineage. Pigment Cell Melanoma Res 21(4):457–463.
48. Patel M, et al. (2014) PTEN deficiency mediates a reciprocal response to IGFI and
mTOR inhibition. Mol Cancer Res 12(11):1610–1620.
49. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-
time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25(4):402–408.
50. Thurman RE, et al. (2012) The accessible chromatin landscape of the human genome.
Nature 489(7414):75–82.
51. Zhang Y, et al. (2008) Model-based analysis of ChIP-Seq (MACS). Genome Biol
9(9):R137.
52. Rozowsky J, et al. (2009) PeakSeq enables systematic scoring of ChIP-seq experiments
relative to controls. Nat Biotechnol 27(1):66–75.
53. Heinz S, et al. (2010) Simple combinations of lineage-determining transcription fac-
tors prime cis-regulatory elements required for macrophage and B cell identities.
Mol Cell 38(4):576–589.
Pattenden et al. PNAS | March 15, 2016 | vol. 113 | no. 11 | 3023
M
ED
IC
A
L
SC
IE
N
CE
S
